Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 15 Jan 2024
Price :
$35
*
At a glance
- Drugs Enzastaurin (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Registrational; Therapeutic Use
- Acronyms ENGAGE
- Sponsors Denovo Biopharma
- 11 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 02 Nov 2021 According to a Denovo Biopharma media release, data from this study will be presented at the Society for NeuroOncology (SNO) Annual Meeting (November 18-21, 2021).
- 08 Jan 2021 According to a Denovo Biopharma media release, this study has received Phase 3 permission from regulatory agencies from US, Canada, and China.